GO:0045721 negative regulation of gluconeogenesis: Hepatic Glucose Output Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045721 describes any process that stops, prevents, or reduces the frequency, rate, or extent of gluconeogenesis, the metabolic pathway that synthesizes glucose from non-carbohydrate precursors.
• The term is a biological_process child of the regulation of gluconeogenesis branch and is critical for maintaining euglycemia during fasting and for preventing excessive hepatic glucose production in type 2 diabetes [2,6].
• Key negative regulators include the transcription factor NFIL3, which directly represses hepatic gluconeogenic gene expression, and the serum- and glucocorticoid-inducible kinase SGK1, which modulates gluconeogenic flux.
• Neuronal inputs, particularly from the ventromedial hypothalamus, suppress glucagon secretion and thereby indirectly inhibit gluconeogenesis.
• Dysregulation of negative regulation of gluconeogenesis contributes to metabolic disorders such as type 2 diabetes, obesity, and triple-negative breast cancer metabolic reprogramming [1,5].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators of gluconeogenesis in hepatocytes and animal models [6,7].
Description
Gluconeogenesis is the metabolic pathway that produces glucose from non-carbohydrate substrates such as lactate, glycerol, and amino acids, and it is essential for maintaining blood glucose levels during fasting. The Gene Ontology (GO) term GO:0045721, negative regulation of gluconeogenesis, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of this pathway. This term is of high interest to researchers studying metabolic diseases, because excessive gluconeogenesis is a hallmark of type 2 diabetes and contributes to hyperglycemia [2,6]. Understanding the molecular players that negatively regulate gluconeogenesis can reveal therapeutic targets for lowering hepatic glucose output [6,7]. Recent studies have identified transcription factors such as NFIL3 as direct negative regulators of hepatic gluconeogenesis, providing a mechanistic basis for this GO term. Additionally, neuronal regulation of glucagon secretion indirectly suppresses gluconeogenesis, highlighting the multi-tissue nature of this process. The term is also relevant to cancer metabolism, where metabolic reprogramming in triple-negative breast cancer involves dysregulated gluconeogenic networks. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0045721, its mechanisms, key genes, disease links, and experimental methods.
negative regulation of gluconeogenesis At A Glance
| GO ID | GO:0045721 |
|---|---|
| GO term | negative regulation of gluconeogenesis |
| Ontology | biological_process |
| Synonym | down regulation of gluconeogenesis, down-regulation of gluconeogenesis, downregulation of gluconeogenesis, inhibition of gluconeogenesis |
| Major function | Suppression of glucose synthesis from non-carbohydrate precursors, primarily in liver and kidney |
| Parent term | regulation of gluconeogenesis |
| Related processes | Insulin signaling, glucagon signaling, hepatic glucose output, fasting response |
| Key regulators | NFIL3, SGK1, insulin, neuronal inputs [2,6,7] |
| Disease relevance | Type 2 diabetes, obesity, metabolic syndrome, triple-negative breast cancer [1,2,5] |
What Is GO:0045721?
GO:0045721, negative regulation of gluconeogenesis, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of gluconeogenesis. In other words, it includes molecular events that suppress the synthesis of glucose from non-carbohydrate precursors such as lactate, glycerol, and amino acids. This regulation can occur at multiple levels, including transcriptional repression of gluconeogenic enzymes, inhibition of key transcription factors like PGC-1alpha and FOXO1, hormonal signaling (e.g., insulin), and neuronal inputs that reduce glucagon secretion [2,6,7]. The term is a biological_process in the Gene Ontology and is a child of regulation of gluconeogenesis.
Why Is negative regulation of gluconeogenesis Important in Cell Biology?
Negative regulation of gluconeogenesis is essential for maintaining glucose homeostasis during fed states and for preventing excessive hepatic glucose production, which is a major driver of hyperglycemia in type 2 diabetes [2,6]. The process integrates hormonal, neuronal, and nutrient signals to fine-tune glucose output, and its dysregulation is implicated in metabolic disorders and cancer [1,2,5]. Understanding this GO term provides a framework for identifying therapeutic targets that can lower blood glucose without causing hypoglycemia.
• Maintains euglycemia by suppressing glucose production when glucose is abundant.
• Prevents excessive hepatic glucose output, a hallmark of type 2 diabetes.
• Integrates insulin and glucagon signaling to balance glucose metabolism.
• Involves neuronal circuits that indirectly inhibit gluconeogenesis via reduced glucagon secretion.
• Dysregulation contributes to obesity and metabolic syndrome.
• Metabolic reprogramming in triple-negative breast cancer involves altered gluconeogenic networks.
• Provides targets for anti-diabetic drugs such as metformin, which affects gluconeogenesis.
• Enables CRISPR-based functional studies of metabolic genes in liver cells [6,7].
• Helps explain inter-individual variability in response to diet and diabetes risk.
• Supports development of precision medicine approaches for metabolic diseases [2,6].
What Happens During negative regulation of gluconeogenesis?
Transcriptional repression of gluconeogenic genes
In simple terms: The cell turns down the production of enzymes that make glucose.
Negative regulation of gluconeogenesis often begins with transcriptional repression of key gluconeogenic enzymes such as PEPCK and G6Pase. The transcription factor NFIL3 directly binds to promoter regions and represses their expression, thereby reducing glucose output. Insulin signaling also leads to phosphorylation and inactivation of FOXO1, a positive regulator of gluconeogenic genes, further suppressing their transcription.
Hormonal and neuronal control
In simple terms: Hormones and brain signals tell the liver to stop making glucose.
Insulin is a primary negative regulator of gluconeogenesis, acting through the PI3K/Akt pathway to inhibit FOXO1 and PGC-1alpha. Conversely, glucagon stimulates gluconeogenesis; thus, negative regulation can occur by suppressing glucagon secretion. Neuronal inputs from the ventromedial hypothalamus reduce glucagon release, indirectly inhibiting hepatic gluconeogenesis.
Kinase-mediated modulation
In simple terms: Enzymes called kinases add phosphate groups to proteins to switch off glucose production.
Serum- and glucocorticoid-inducible kinase 1 (SGK1) plays a role in regulating hepatic gluconeogenesis. Studies show that SGK1 can modulate gluconeogenic flux, and its inhibition may reduce glucose output. Other kinases such as AMPK also negatively regulate gluconeogenesis by phosphorylating and inhibiting key transcription factors.
Metabolic and epigenetic feedback
In simple terms: Metabolites and chemical tags on DNA can dial down glucose production.
Diet and gut microbiota influence host epigenetics, which can affect gluconeogenic gene expression. For example, short-chain fatty acids produced by microbiota can modulate hepatic metabolism. Additionally, metabolites such as AMP and NAD+ serve as sensors that feed back to inhibit gluconeogenesis when energy status is high.
Integration with systemic glucose homeostasis
In simple terms: The whole body coordinates to keep blood sugar stable.
Negative regulation of gluconeogenesis is integrated with other metabolic pathways, including glycolysis and lipogenesis. Insulin promotes glycolysis and lipogenesis while suppressing gluconeogenesis, ensuring that glucose is stored rather than produced. This coordination is critical for maintaining euglycemia and preventing hyperglycemia.
Key Genes Involved in GO:0045721 negative regulation of gluconeogenesis
The following genes and proteins are key players in the negative regulation of gluconeogenesis, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NFIL3 | Transcription factor that represses hepatic gluconeogenic genes | Direct negative regulator; knockout models show increased gluconeogenesis |
| SGK1 | Kinase that modulates hepatic gluconeogenesis | Potential target for diabetes; regulates gluconeogenic flux |
| FOXO1 | Transcription factor activated by glucagon; insulin inhibits it | Central node in insulin-mediated suppression of gluconeogenesis |
| PGC-1alpha | Coactivator that promotes gluconeogenic gene expression | Inhibited by insulin signaling; target for anti-diabetic drugs |
| PEPCK | Rate-limiting enzyme of gluconeogenesis | Transcriptional repression reduces glucose output |
| G6Pase | Enzyme that catalyzes the final step of gluconeogenesis | Repressed by NFIL3 and insulin |
| INSR | Insulin receptor; initiates signaling that inhibits gluconeogenesis | Mutations cause insulin resistance and hyperglycemia |
| IRS1/2 | Insulin receptor substrates; mediate insulin signaling | Downregulation impairs negative regulation of gluconeogenesis |
| AKT | Kinase that phosphorylates FOXO1, leading to its exclusion from nucleus | Key mediator of insulin action |
| AMPK | Energy sensor that inhibits gluconeogenesis when activated | Target of metformin; phosphorylates CRTC2 and FOXO1 [2,8] |
| CRTC2 | Coactivator that stimulates gluconeogenic gene expression | Inhibited by AMPK and insulin signaling |
| SLC7A11 | Cystine/glutamate antiporter; affects redox and metabolism | Targeting SLC7A11 improves efferocytosis in diabetes, indirectly affecting gluconeogenesis |
| GCGR | Glucagon receptor; activation stimulates gluconeogenesis | Antagonists reduce glucose output |
| GLP1R | GLP-1 receptor; activation reduces glucagon secretion | Agonists indirectly inhibit gluconeogenesis |
| SIRT1 | Deacetylase that modulates gluconeogenic gene expression | Regulates PGC-1alpha activity |
| FBP1 | Fructose-1,6-bisphosphatase; gluconeogenic enzyme | Its expression is repressed by insulin |
| PCK1 | Cytosolic PEPCK; key gluconeogenic enzyme | Transcriptional repression by NFIL3 |
| PCK2 | Mitochondrial PEPCK; involved in gluconeogenesis | Potential target in cancer metabolism |
How Is negative regulation of gluconeogenesis Regulated?
Negative regulation of gluconeogenesis is controlled by a complex network of hormonal, neuronal, and metabolic signals. Insulin is the primary hormone that suppresses gluconeogenesis, acting through the PI3K/Akt pathway to inhibit FOXO1 and PGC-1alpha. Glucagon opposes insulin by stimulating gluconeogenesis; thus, inhibition of glucagon secretion or action reduces glucose output. Neuronal inputs from the hypothalamus can suppress glucagon release, indirectly inhibiting gluconeogenesis. At the cellular level, kinases such as AMPK and SGK1 modulate gluconeogenic flux in response to energy status and stress. Transcriptional repressors like NFIL3 directly downregulate gluconeogenic genes. Additionally, epigenetic modifications influenced by diet and gut microbiota can alter the expression of gluconeogenic enzymes. Metformin, a first-line anti-diabetic drug, inhibits hepatic gluconeogenesis partly through AMPK activation and mitochondrial complex I inhibition.
negative regulation of gluconeogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NFIL3 | Type 2 diabetes, hyperglycemia | Liver-specific knockout mice, hepatocyte cell lines |
| SGK1 | Type 2 diabetes, metabolic syndrome | SGK1 knockout mice, CRISPR point mutations |
| FOXO1 | Insulin resistance, diabetes | Knock-in mice with phosphorylation-deficient FOXO1 |
| SLC7A11 | Diabetes, impaired wound healing | Conditional knockout in dendritic cells |
| PCK1 | Type 2 diabetes, cancer metabolism | Overexpression and knockout in hepatocytes [1,6] |
Type 2 diabetes and insulin resistance
In type 2 diabetes, impaired negative regulation of gluconeogenesis leads to excessive hepatic glucose production, contributing to hyperglycemia. Insulin resistance reduces the ability of insulin to suppress gluconeogenic gene expression, and glucagon levels are often elevated. NFIL3 downregulation or dysfunction may exacerbate this condition. Therapeutic strategies aim to enhance negative regulation, for example by targeting SGK1 or AMPK [7,8].
Obesity and metabolic syndrome
Obesity is associated with chronic low-grade inflammation and altered gut microbiota, which can affect host epigenetics and gluconeogenic gene expression. Dysregulation of negative regulators like AMPK and SIRT1 contributes to increased hepatic glucose output. Weight loss and dietary interventions can improve negative regulation of gluconeogenesis.
Triple-negative breast cancer
Metabolic reprogramming in triple-negative breast cancer involves dysregulated gluconeogenic networks. Comprehensive metabolomics and transcriptomics have uncovered alterations in glucose metabolism, including gluconeogenesis-related pathways. Targeting these pathways may offer therapeutic opportunities.
Diabetes-related wound healing
Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes, suggesting a link between metabolic regulation and immune function. Although direct evidence for gluconeogenesis is limited, this highlights the broader impact of metabolic dysregulation in diabetes.
From negative regulation of gluconeogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NFIL3 directly repress gluconeogenic genes? | Liver-specific NFIL3 knockout mice and hepatocyte cell lines |
| What is the role of SGK1 in hepatic gluconeogenesis? | SGK1 knockout mice and CRISPR point mutations |
| How does insulin signaling inhibit FOXO1? | Knock-in mice expressing FOXO1 mutants |
| Can targeting SLC7A11 improve diabetic wound healing? | Conditional knockout mice and overexpression models |
| What is the impact of gut microbiota on gluconeogenesis? | Germ-free mice and fecal microbiota transplantation |
| How does metformin affect gluconeogenesis? | AMPK knockout mice and proteomic analysis |
How to Study the negative regulation of gluconeogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify transcriptional repression of gluconeogenic genes |
| Metabolomics | Metabolite levels and flux | Assess gluconeogenic activity in cells and tissues |
| Proteomics | Protein abundance and modifications | Discover biomarkers and drug effects |
| CRISPR screening | Gene function at scale | Identify negative regulators of gluconeogenesis |
| ChIP-seq | Transcription factor binding | Map NFIL3 binding to gluconeogenic promoters |
| Western blot | Protein expression and phosphorylation | Validate signaling changes (e.g., Akt, FOXO1) |
| Glucose production assay | Hepatic glucose output | Measure gluconeogenesis in primary hepatocytes |
Transcriptomics and RNA-seq
RNA sequencing can quantify expression of gluconeogenic genes and identify transcriptional changes upon manipulation of negative regulators. Studies have used transcriptomics to uncover dysregulated networks in triple-negative breast cancer, including gluconeogenesis-related pathways.
Metabolomics
Metabolomics measures small-molecule metabolites such as glucose, lactate, and amino acids to assess flux through gluconeogenesis. Comprehensive metabolomics has been applied to understand metabolic reprogramming in cancer.
Proteomics
Proteomic analysis of urine or tissue can reveal changes in protein abundance related to gluconeogenesis. For example, urine proteome analysis explored the effects of metformin on the body, providing insights into metabolic regulation.
CRISPR screening and functional genomics
CRISPR library screening enables unbiased identification of genes that regulate gluconeogenesis. Pooled screens with metabolic readouts can uncover novel negative regulators.
How CRISPR Can Be Used to Study GO:0045721 negative regulation of gluconeogenesis
Knockout
CRISPR knockout of candidate negative regulators such as NFIL3 or SGK1 in hepatocyte cell lines or mouse liver can determine whether they are required for suppressing gluconeogenesis. For example, NFIL3 knockout leads to increased gluconeogenic gene expression.
Point Mutation
Point mutations can be introduced to study phosphorylation sites or DNA-binding domains. For instance, mutating specific residues in FOXO1 can prevent its inactivation by Akt, thereby impairing negative regulation of gluconeogenesis.
Knock-in
Knock-in of tagged versions of gluconeogenic enzymes or regulators allows for tracking their localization and interactions. This can be used to study the dynamics of NFIL3 binding to promoters.
Overexpression
Overexpression of negative regulators like NFIL3 or SGK1 can suppress gluconeogenesis and reduce glucose output. This approach is useful for validating sufficiency in cell models [6,7].
How EDITGENE Supports negative regulation of gluconeogenesis Research
Researchers studying negative regulation of gluconeogenesis-related genes often need to determine whether a candidate gene is causally involved in suppressing glucose production. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of gluconeogenesis research.
Frequently Asked Questions About negative regulation of gluconeogenesis
What is negative regulation of gluconeogenesis?
Negative regulation of gluconeogenesis (GO:0045721) refers to any process that stops, prevents, or reduces the frequency, rate, or extent of gluconeogenesis, the synthesis of glucose from non-carbohydrate precursors.
What genes are involved in negative regulation of gluconeogenesis?
Key genes include NFIL3, SGK1, FOXO1, PGC-1alpha, AMPK, and SIRT1, among others [2,6,7].
How does insulin inhibit gluconeogenesis?
Insulin activates the PI3K/Akt pathway, leading to phosphorylation and inactivation of FOXO1 and inhibition of PGC-1alpha, thereby suppressing gluconeogenic gene expression.
What is the role of NFIL3 in gluconeogenesis?
NFIL3 is a transcription factor that directly represses hepatic gluconeogenic genes such as PEPCK and G6Pase, acting as a negative regulator.
How is SGK1 involved in gluconeogenesis?
SGK1 modulates hepatic gluconeogenesis, and its inhibition may reduce glucose output; it is a potential therapeutic target for diabetes.
What diseases are associated with dysregulated negative regulation of gluconeogenesis?
Type 2 diabetes, obesity, metabolic syndrome, and triple-negative breast cancer are associated with dysregulation of this process [1,2,5].
How can CRISPR be used to study negative regulation of gluconeogenesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of candidate genes in hepatocytes and animal models [6,7].
What methods are used to measure gluconeogenesis?
Methods include glucose production assays, RNA-seq, metabolomics, proteomics, and CRISPR screening [1,3,6,8].
What is the role of AMPK in gluconeogenesis?
AMPK is an energy sensor that inhibits gluconeogenesis by phosphorylating CRTC2 and FOXO1, and it is a target of metformin [2,8].
How does the gut microbiota affect gluconeogenesis?
Diet and gut microbiota can influence host epigenetics and metabolic pathways, including gluconeogenesis, through metabolites such as short-chain fatty acids.
Conclusion
GO:0045721, negative regulation of gluconeogenesis, is a critical biological process that maintains glucose homeostasis by suppressing hepatic glucose production. Key regulators such as NFIL3, SGK1, and insulin signaling pathways have been identified through rigorous research [2,6,7]. Dysregulation of this process contributes to type 2 diabetes, obesity, and cancer metabolism [1,2,5]. Advances in CRISPR-based models and multi-omics technologies are accelerating the discovery of novel therapeutic targets. EDITGENE provides comprehensive services to support functional studies of this pathway, from knockout to overexpression and library screening.
References
- 1. Gong S et al.. 2024. Comprehensive analysis of the metabolomics and transcriptomics uncovers the dysregulated network and potential biomarkers of Triple Negative Breast Cancer.. J Transl Med 22(1):1016 PMID: 39529035
- 2. Thorens B. 2022. Neuronal regulation of glucagon secretion and gluconeogenesis.. J Diabetes Investig 13(4):599-607 PMID: 34989155
- 3. Kuchina A et al.. 2021. Microbial single-cell RNA sequencing by split-pool barcoding.. Science 371(6531) PMID: 33335020
- 4. Maschalidi S et al.. 2022. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes.. Nature 606(7915):776-784 PMID: 35614212
- 5. Cuevas-Sierra A et al.. 2019. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.. Adv Nutr 10(suppl_1):S17-S30 PMID: 30721960
- 6. Kang G et al.. 2017. NFIL3 is a negative regulator of hepatic gluconeogenesis.. Metabolism 77:13-22 PMID: 29132537
- 7. Xu Z et al.. 2023. Role of serum- and glucocorticoid-inducible kinase 1 in the regulation of hepatic gluconeogenesis.. J Mol Endocrinol 71(2) PMID: 37283531
- 8. Chen Y et al.. 2025. Exploring the Effects of Metformin on the Body via the Urine Proteome.. Biomolecules 15(2) PMID: 40001544
